Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
Dr. Emily Andaya joins Louise Campbell and Roger Green to discuss the American Heart Association’s CKM initiative and why she believes it should include “L” for liver.
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
This episode focuses on “multi-metabolic medicine,” including a roundtable whose guests run multi-metabolic practices in the US and Spain and an interview with Dr. Emily Andaya, an advocate for including the liver in the American Heart Associations’s CKM initiative.
Predictive Health Intelligence Medical Director Tim Jobson joins Louise Campbell and Roger Green to provide an update on PHI’s Somerset project and other activities.
LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos join Roger Green to discuss the launch of America’s first virtual hepatology clinic and the reason they created it.
First Six Months, Part I: Jörn Schattenberg cites two recent papers to describe the role proteomics might play in tailoring patient treatment plans.
Jörn Schattenberg, Louise Campbell and Roger Green discuss how future NITs can help prescribers decide where to focus therapy, LiverRight executives describe the first virtual hepatology clinic and simple large-scale data analysis identifies high-risk liver patients unaware of their risks.
